Mismatch repair protein MLH1 and MSH2 expression was retained, molecular MSI testing (Bethesda markers plus the mononucleotide marker CAT25 (21) additionally confirmed a microsatellite-stable tumor. Here, MSH2 is linked to neoplasm.